The OHC Genetic Risk Evaluation and Testing Program (GREAT) provides testing and counseling for people who may be at risk for a hereditary cancer syndrome. Our team of Cancer Genetic Specialists helps at-risk individuals make informed decisions in accordance with their health care needs, preferences and values. You don’t have to be an OHC patient to be seen by an OHC Cancer Genetic Specialist.
OHC Cancer Genetic Specialists analyze your personal and family history to determine if there is a risk for a hereditary cancer syndrome. They will discuss:
- Your personal and medical history and cancer screening history
- Your family history of cancer
- Your risk for a hereditary cancer syndrome
- Whether or not you should have further genetic testing
- Your results in great detail and next steps
What is genetic testing?
Genetic testing can determine if you have a disease-related gene condition that may put you at higher risk of getting cancer before symptoms appear.
Who is at risk?
You may be at higher risk if you have certain types of cancers or cancer in your family. Your genes may predict your risk of cancer, and certain genetic tests may help your doctors provide better screening or treatment options.
Who should consider testing?
Some people are at higher risk of developing certain types of cancer because they have an inherited gene condition. If you have been diagnosed with cancer before the age of 50, have multiple family members with cancer, or have experienced multiple cancers, you may want to speak with your doctor about genetic counseling.
Where can I get genetic testing?
For your convenience, you can travel to OHC’s Blue Ash, Kenwood, Fairfield, Hamilton, Eastgate, and West locations to obtain genetic testing, or you can schedule a telehealth appointment.
If you’d like to talk with someone about genetic testing, call us at 1-888-649-4800 and we’d be happy to schedule an appointment for you with one of our specialists. To learn more about our program, read What is Genetic Testing and Why is it so Important? GREAT is a program developed by The US Oncology Network.
